News Releases

DUBLIN, May 4, 2016 /PRNewswire/ -- Allergan (NYSE: AGN) today announced that its data will be presented during the 2016 American Society of Cataract and Refractive Surgery (ASCRS) Symposium & Congress in New Orleans, Louisiana, May 6-10, 2016.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

The scheduled times (noted in local Central Time) of the seven Allergan presentations and locations at the New Orleans Ernest N. Morial Convention Center are as follows:

Dry Eye:

• Evaluation of the Effect of Intranasal Lacrimal Neurostimulation on Tear Production in Subjects with Dry Eye: Nonrandomized Open-Label Study
  • Date and Time: Monday, May 9, 2016, 9:04 AM-9:09 AM
  • Room: 209
  • Categories: Dry Eye: Diagnosis and Treatment
    
• Comparison of Intranasal Lacrimal Neurostimulation with Two Control Applications for Acute Tear Production in Moderate to Severe Dry Eye Patients: Randomized Trial
  • Date and Time: Monday, May 9, 2016, 9:09 AM-9:14 AM
  • Room: 209
  • Categories: Dry Eye: Diagnosis and Treatment

Glaucoma:

• One-Year Results of an Ab Interno Gelatin Stent as a Standalone Procedure for the Treatment of Mild to Moderate Primary Open-Angle Glaucoma
  • Date and Time: Saturday, May 7, 2016, 1:30-1:35 PM
  • Room: 224
  • Categories: Glaucoma: MIGS
    
• Results of Gelatin Stent Implantation with Mitomycin-C to Treat Open-Angle Glaucoma as a Solo Procedure or in Combination with Cataract Surgery
  • Date and Time: Saturday, May 7, 2016, 3:02-3:07 PM
  • Room: 223
  • Categories: Glaucoma: MIGS/Canaloplasty
    
• The XEN Procedure: 1-Year Results of an Ab-Interno Gelatin Stent Along with Cataract Surgery for the Treatment of Glaucoma
  • Date and Time: Sunday, May 8, 2016, 3:07-3:12 PM
  • Room: 224
  • Categories: Glaucoma: MIGS, Trabeculectomy
    
• Development of a Minimally Invasive Collagen Stent for Treating Glaucoma: First 975 Eyes Treated
  • Date and Time: Sunday, May 8, 2016, 3:17-3:22 PM
  • Room: 224
  • Categories: Glaucoma: MIGS, Trabeculectomy
    
• Bimatoprost Sustained-Release Implants for Glaucoma Therapy: Safety and Efficacy through Month 6 in a Phase 1/2 Clinical Trial
  • Date and Time: Monday, May 9, 2016, 1:17-1:22 PM
  • Room: 217
  • Categories: Glaucoma: Surgical Technique, Trabeculotomy

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model—Growth Pharma.  Allergan is focused on developing, manufacturing, and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines, and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, health care providers, and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Investors:     
Lisa DeFrancesco   
(862) 261-7152  

Media:    
Mark Marmur  
(973) 906-1526

SOURCE Allergan